AwesomeCapital
Wednesday, October 31, 2018
Takeda Reports Second Quarter FY2018 Results
›
Strong underlying growth driven by business momentum and strict OPEX discipline; Underlying Revenue +4.2%, Underlying Core Earnings +31.8%...
Is the Biotech Bull Market Over?
›
…And How Long Will The Bear Market Last? It may not have always felt like it, but biotech has been in a bull market mode over the past t...
Galderma, Nestlé Skin Health, Positive Phase 2b Atopic Dermatitis Med Study
›
Galderma , Nestlé Skin Health’s medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemoliz...
Sarepta CEO acquires 16,695 common shares
›
In a regulatory filing, Sarepta Therapeutics president and CEO Douglas S. Ingram disclosed the acquisition of 16,695 common shares of the ...
Clovis price target lowered to $18 from $33 at Piper Jaffray
›
Piper Jaffray analyst Joseph Catanzaro lowered his price target on Clovis to $18 and kept his Neutral rating while also lowering his FY19 ...
Twist Bioscience 5M share IPO priced at $14.00
›
The deal priced at the low end of $14.00-$16.00 range. JPMorgan and Cowen acted as joint book running managers for the offering. https:/...
Orchard Therapeutics 14.3M share IPO priced at $14.00
›
The deal was upsized from 13.33M and priced at the low end of the $14.00-$16.00 range. JPMorgan, Goldman Sachs, Cowen and Wedbush are acti...
‹
›
Home
View web version